HealthyPhase 2NCT07085468

A Study of LY3549492 in Healthy Weight Adult Participants

A Phase 2 study testing LY3549492 in people with Healthy, run by Eli Lilly and Company at 21 sites in 2 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Trial summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months. Read more about this study

Who is it for?: Ages 55 to 80 years
Conditions the study is for: Healthy
What is being tested?: LY3549492
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 1 participants
Where: 21 sitesin 2 countries
Study dates: 21 Jul 2025to 14 Aug 2025
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 55 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
Have had a stable body weight for 3 months prior to screening

Who cannot join

Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
Have:
type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
rare forms of diabetes mellitus, or
hemoglobin A1c (HbA1c) >8%
Have poorly controlled hypertension

Show all 15Show fewer

Have any of the following cardiovascular conditions within 12 months prior to screening:
acute myocardial infarction
stroke
unstable angina, or
hospitalization due to congestive heart failure.
Have a history of New York Heart Association Functional Classification III or IV congestive heart failure
Have signs and symptoms of liver disease
Have a history of pancreatitis
Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening

Trial locations and contacts

21 sites in 2 countries.

Country

City, postcode or hospital

21 sites in 2 countries

United States11 sites

JEM Research Institute
Atlantis, Florida, 33462
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, 60640
Valley Clinical Trials, Inc.
Covina, California, 91723
Alliance for Multispecialty Research, LLC
Lexington, Kentucky, 40509
Trial Management Associates
Myrtle Beach, South Carolina, 29572
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, 73069
Valley Clinical Trials, Inc.
Northridge, California, 91325
Peninsula Research Associates
Rolling Hills Estates, California, 90274
Artemis Institute for Clinical Research
San Diego, California, 92103
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
Clinical Research Atlanta
Stockbridge, Georgia, 30281

Other trials in United States

Canada10 sites

Viacar Recherche Clinique
Greenfield Park, J4V 2G8
Apex Trials
Guelph, N1G 0B4
OCT Research ULC
Kelowna, V1Y 1Z9
Clinique Mémoire de Montréal
Montreal, H3G 1H9
Ottawa Memory Clinic
Ottawa, K1Z 1G3
Richmond Clinical Trials
Richmond, V6V 2L1
Q&T Research Sherbrooke Inc.
Sherbrooke, J1J 2G2
Toronto Memory Program
Toronto, M3B 2S7
BioPharma Services
Toronto, M9L 3A2
Diex Recherche Trois-Rivieres
Trois-Rivières, G9A 4P3

Other trials in Canada

About this study

Official title: A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

Conditions: Healthy
Being tested: LY3549492, Placebo
Keywords: Elderly, Body Weight, Body Composition
Medical subject headings: Body Weight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LY3549492Drug
Administered orally
PlaceboDrug
Administered orally

Study groups in NCT07085468
Study group	Role	What they receive
15 mg LY3549492	Experimental	Participants were planned to receive 15 milligrams (mg) LY3549492 orally once daily for 48 weeks. Receives: Drug: LY3549492
60 mg LY3549492	Experimental	Participants were planned to receive 60 mg LY3549492 orally once daily for 48 weeks. Receives: Drug: LY3549492
Placebo	Placebo comparator	Participants were planned to receive matching placebo orally once daily for 48 weeks. Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Measured: Baseline through Week 48

Secondary outcomes (2)

Percent Change From Baseline in Body Weight
Measured: Baseline, Week 24, Week 48
Number of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal
Measured: Baseline through Week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 Jul 202514 Aug 2025

First posted25 Jul 2025
Study start21 Jul 2025
Primary completion14 Aug 2025
Study completion14 Aug 2025

Why it stopped: Study terminated for strategic business reasons

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for HealthyStudies of the same condition, open and under way.
More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 1 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07085468
Sponsor's protocol ID: 27357
Other IDs: J3H-MC-GZNI
Status last verified: Sep 2026
First submitted: 18 Jul 2025
Last updated: 21 Sep 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2
ClinicalTrials.gov ID: NCT07085468
Acronym / sponsor ID: 27357
Conditions: Healthy
Keywords: Elderly, Body Weight, Body Composition
Phase: Phase 2
Study type: Interventional
Recruitment status: TerminatedReason stopped: Study terminated for strategic business reasons
Enrolment: 1 participants (actual)
Lead sponsor: Eli Lilly and CompanyIndustry (pharma, biotech, devices)
Study start: 21 Jul 2025 (actual)
Primary completion: 14 Aug 2025 (actual)
Study completion: 14 Aug 2025 (actual)
First posted: 25 Jul 2025 (actual)
Results: Posted 21 Sep 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 3

Arm	Type	Receives
15 mg LY3549492	Experimental	Drug: LY3549492Participants were planned to receive 15 milligrams (mg) LY3549492 orally once daily for 48 weeks.
60 mg LY3549492	Experimental	Drug: LY3549492Participants were planned to receive 60 mg LY3549492 orally once daily for 48 weeks.
Placebo	Placebo comparator	Drug: PlaceboParticipants were planned to receive matching placebo orally once daily for 48 weeks.

Who may qualify

Ages: 55 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
Have had a stable body weight for 3 months prior to screening

Key exclusion criteria (15 listed)

Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
Have:
Have poorly controlled hypertension
Have any of the following cardiovascular conditions within 12 months prior to screening:
Have a history of New York Heart Association Functional Classification III or IV congestive heart failure

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LY3549492Administered orally	Drug	15 mg LY3549492, 60 mg LY3549492
PlaceboAdministered orally	Drug	Placebo

Primary outcome

Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Week 48

2 secondary outcomes

Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 24, Week 48
Number of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal
Time frame: Baseline through Week 48

Results and safety

Results posted to the registry on 21 Sep 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
15 mg LY3549492	0	0
60 mg LY3549492	1	0
Placebo	0	0

Primary outcome: Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

Time frame: Baseline through Week 48

Population analysed: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data was collected and no analyses could be performed.

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events
15 mg LY3549492	0 of 0	0 of 0
60 mg LY3549492	0 of 0	0 of 0
Placebo	0 of 0	0 of 0

Limitations and caveats (from the sponsor): The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected and no analyses could be performed.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Related trials for Healthy

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director

Eli Lilly and Company

21 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing LY3549492 in people with Healthy, run by Eli Lilly and Company at 21 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 21 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Sep 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through Week 48). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07085468.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.